NewOmics Status
The company raised $3.9 million of Series A venture funding from undisclosed investors on August 9, 2018, putting the company's pre-money valuation at $16 million.
Developer of a biotechnology platform intended to offer innovative and integrative personalized healthcare. The company's platform offers proteomics, metabolomics, and lipidomics analyses of small amounts of biological samples, including human plasma and mammalian cells, as well as host cell proteins, CHO cell culture media and antibody drugs, enabling doctors to empower mass spectrometry through integration and miniaturization.
Year Founded
2011
General Information
-
Website
-
Business Status
Generating Revenue
-
Ownership Status
Privately Held (backing)
-
Financing Status
Venture Capital-Backed
NewOmics News and Updates
Metabolomics reveals molecular signatures | CCID
Dove Medical Press | November 4, 2023
The Changing Face of Chromatography
BSA bureau | October 31, 2023
Liquid Chromatography Mass Spectrometry (LCMS) is projected to ...
Kalkine Media | October 20, 2023
World Leaders in Proteomics and Genomics to Convene at the 2nd ...
GlobeNewswire | September 20, 2023
SEPTIN3 Promotes Progression of Triple-Negative Breast Cancer ...
Dove Medical Press | September 12, 2023
Precision nutrition report concludes "We know next to nothing"
NutraIngredients.com | August 29, 2023
NewOmics's Verticals
NewOmics Primary Industry Sector / Group / Code
NewOmics's Trends
NewOmics Metrics
SimilarWeb Unique Visitors
Majestic Referring Domains
Headquarters
-
HQ Address Line 1804 Heinz Avenue
-
HQ Address Line 2Suite 150
-
HQ CityBerkeley
-
HQ State/ProvinceCalifornia
-
HQ Post Code94710
-
HQ CountryUnited States
NewOmics's Keywords
mood_badFeed is empty.
Add a review